Theranostics 2020; 10(19):8468-8478. doi:10.7150/thno.46241 This issue Cite

Research Paper

Serum piRNA-54265 is a New Biomarker for early detection and clinical surveillance of Human Colorectal Cancer

Dongmei Mai1#, Yanfen Zheng1#, Huan Guo2,6#, Peirong Ding3#, Ruihong Bai1, Mei Li4, Ying Ye1, Jialiang Zhang1, Xudong Huang1, Dingxin Liu3, Qiaoqi Sui3, Ling Pan1, Jiachun Su1, Junge Deng1, Guandi Wu1, Rui Li1, Shuang Deng1, Yansen Bai2, Yanan Ligu2, Wen Tan5, Chen Wu5, Tangchun Wu2,6✉, Jian Zheng1✉, Dongxin Lin1,5✉

1. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
2. Department of Occupational & Environmental Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
3. Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
4. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
5. Department of Etiology and Carcinogenesis, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
6. Key Laboratory of Environment and Health, Ministry of Education & Ministry of Environmental Protection, State Key Laboratory of Environmental Health (Incubating), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
#These authors contributed equally to this work.

Citation:
Mai D, Zheng Y, Guo H, Ding P, Bai R, Li M, Ye Y, Zhang J, Huang X, Liu D, Sui Q, Pan L, Su J, Deng J, Wu G, Li R, Deng S, Bai Y, Ligu Y, Tan W, Wu C, Wu T, Zheng J, Lin D. Serum piRNA-54265 is a New Biomarker for early detection and clinical surveillance of Human Colorectal Cancer. Theranostics 2020; 10(19):8468-8478. doi:10.7150/thno.46241. https://www.thno.org/v10p8468.htm
Other styles

File import instruction

Abstract

Graphic abstract

Background: Our previous study has demonstrated an oncogenic role of PIWI-interacting RNA-54265 (piR-54265) in colorectal cancer (CRC). Here, we investigate whether it can be a blood biomarker for population screening and clinical applications.

Methods: Serum piR-54265 levels were determined by a digital PCR method in 209 cancer-free healthy controls, 725 patients with CRC, 1303 patients with other types of digestive cancer and 192 patients with benign colorectal tumors. A prospective case-control analysis was conducted to assess the predictive value of serum piR-54265 for future CRC diagnosis. Receiver operating characteristic (ROC) curve was constructed to quantify the diagnostic performance of serum piR-54265 levels by assessing its sensitivity, specificity and respective areas under curve (AUC). The odds ratios (ORs) were computed using multivariate logistic regression models.

Results: Serum piR-54265 levels were significantly elevated only in patients with CRC compared with controls and patients with other cancer types. The AUC for recognizing CRC was 0.896 (95% CI, 0.874-0.914), with a sensitivity and specificity being 85.7% and 65.1% at 1500 copies/µL as a cut-off value. The serum piR-54265 levels in patients declined substantially after surgery but increased significantly again when tumor relapses. The prediagnostic serum piR-54265 levels were significantly associated with future CRC diagnosis, with the ORs of 7.23, 2.80, 2.45, and 1.24 for those whose CRC was diagnosed within 1, 2, 3 and >3 years. Serum piR-54265 test is more sensitive than other blood CRC markers.

Conclusion: Serum piR-54265 may serve as a valuable biomarker for CRC screening, early detection and clinical surveillance.

Keywords: colorectal cancer, serum piRNA-54265, biomarker


Citation styles

APA
Mai, D., Zheng, Y., Guo, H., Ding, P., Bai, R., Li, M., Ye, Y., Zhang, J., Huang, X., Liu, D., Sui, Q., Pan, L., Su, J., Deng, J., Wu, G., Li, R., Deng, S., Bai, Y., Ligu, Y., Tan, W., Wu, C., Wu, T., Zheng, J., Lin, D. (2020). Serum piRNA-54265 is a New Biomarker for early detection and clinical surveillance of Human Colorectal Cancer. Theranostics, 10(19), 8468-8478. https://doi.org/10.7150/thno.46241.

ACS
Mai, D.; Zheng, Y.; Guo, H.; Ding, P.; Bai, R.; Li, M.; Ye, Y.; Zhang, J.; Huang, X.; Liu, D.; Sui, Q.; Pan, L.; Su, J.; Deng, J.; Wu, G.; Li, R.; Deng, S.; Bai, Y.; Ligu, Y.; Tan, W.; Wu, C.; Wu, T.; Zheng, J.; Lin, D. Serum piRNA-54265 is a New Biomarker for early detection and clinical surveillance of Human Colorectal Cancer. Theranostics 2020, 10 (19), 8468-8478. DOI: 10.7150/thno.46241.

NLM
Mai D, Zheng Y, Guo H, Ding P, Bai R, Li M, Ye Y, Zhang J, Huang X, Liu D, Sui Q, Pan L, Su J, Deng J, Wu G, Li R, Deng S, Bai Y, Ligu Y, Tan W, Wu C, Wu T, Zheng J, Lin D. Serum piRNA-54265 is a New Biomarker for early detection and clinical surveillance of Human Colorectal Cancer. Theranostics 2020; 10(19):8468-8478. doi:10.7150/thno.46241. https://www.thno.org/v10p8468.htm

CSE
Mai D, Zheng Y, Guo H, Ding P, Bai R, Li M, Ye Y, Zhang J, Huang X, Liu D, Sui Q, Pan L, Su J, Deng J, Wu G, Li R, Deng S, Bai Y, Ligu Y, Tan W, Wu C, Wu T, Zheng J, Lin D. 2020. Serum piRNA-54265 is a New Biomarker for early detection and clinical surveillance of Human Colorectal Cancer. Theranostics. 10(19):8468-8478.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image